Skip to main content

Table 3 Changes on Optical Coherence Tomography derived endpoints between baseline and follow-up

From: Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study

 

Baseline

Follow-up

Change between baseline and follow up

P value

Exenatide (n = 19)

Control (n = 17)

P value

Exenatide (n = 16)

Control (n = 17)

P value

Exenatide (n = 15)

Control (n = 17)

P value

Strut analysis

 Covered struts per lesion, %

95.0 (88.7–98.5)

91.4 (88.8–98.5)

0.692a

 Covered struts > 40 µm, %

   

79.4 (35.0–95.0)

64 (34.3–90.5)

0.589a

   

 Malapposition > 300 µm,%

0.8 (1.5)

1.5 (2.7)

0.347b

0.4 (0.8)

1.4 (4.2)

0.368b

− 0.2 (1.2)

− 0.0 (2.5)

0.829b

 Malapposition volume, mm3

11 (4.8)

13.5 (8.4)

0.285b

2.2 (2.6)

3.7 (5.3)

0.322b

− 9 (5.4)

− 9.2 (7.5)

0.892b

 Mean NIH area, mm2

1.3 (0.4)

1.1 (0.5)

0.423b

 NIH area at maximal obstruction, mm2

1.2 (1–2.3)

1.1 (0.7–1.9)

0.407a

 NIH stenosis, %

15.5 (10.6–19.2)

14.7 (11–17.1)

0.801a

 NIH volume at maximal obstruction, mm3

33.8 (20)

33.8 (17.4)

1.000b

 Maximal neo-intimal thickness at maximal obstruction, mm

0.2 (0.1–0.3)

0.2 (0.1–0.6)

0.471a

 Total number of struts analyzed per lesion, n

2031 (664)

2545.5 (1187)

0.113b

2154 (924)

2579 (1380)

0.304b

   

 Number of struts per cross-section, n

10.2 (1.6)

10.3 (1.4)

0.863b

10.9 (1.6)

10.6 (1.6)

0.690b

   

Stenosis segment

 Minimum lumen diameter at maximal obstruction, mm

2.4 (0.4)

2.3 (0.5)

0.464b

2.3 (0.5)

2.1 (0.6)

0.517b

− 0.2 (0.4)

− 0.2 (0.4)

0.798b

 Mean in-stent minimal lumen diameter, mm

2.9 (0.4)

2.7 (0.4)

0.261b

2.8 (0.4)

2.7 (0.5)

0.382b

− 0.1 (0.2)

− 0.0 (0.2)

0.165b

 CS lumen area at maximal obstruction, mm2

6.1 (1.8)

5.1 (1.8)

0.122b

5 (2)

4.4 (2.2)

0.362b

− 0.6 (− 0.2–1.6)

− 0.6 (0.3–1.0)

0.635a

 Lumen area stenosis (mean area as reference), %

23.2 (3.6–32.7)

17.3 (10–27.8)

0.692a

30.4 (17.7–46.3)

32.7 (18.2–46.1)

0.857a

13.7 (3.6–24.6)

12.6 (− 5–29.5)

0.813a

 CS stent area at maximal obstruction, mm2

6.1 (1.8)

5.1 (1.8)

0.097b

6.6 (2.1)

5.8 (2.1)

0.272b

0.2 (1.8)

0.9 (1.0)

0.231b

 Mean in-stent CS area, mm2

8.1 (2.2)

7 (2.0)

0.134b

7.6 (1.9)

6.9 (2.7)

0.885b

0.3 (1)

1.1 (1.0)

0.054b

 In-stent lumen volume, mm3

204.7 (155.8–296)

192.2 (154.9–283.7)

0.937a

246.8 (155.3–276)

187.1 (123.6–289)

0.756a

− 17.8 (− 62.2–20.1)

− 2.6 (− 34–62.4)

0.268a

 In-stent stent volume, mm3

157.4 (136–273)

166.5 (104.8–258)

0.537a

228.9 (136.1–297.3)

206.9 (145.3–312.3)

0.971a

13.4 (-36.3–71)

48.5 (27.3–140.5)

0.048a

  1. Differences between groups at baseline, follow-up and in changes between baseline and follow-up in OCT-derived endpoints. Tested with aMann-Whitney U test, bStudent’s T-test. CS cross-sectional, NIH neo-intima hyperplasia